CN100558368C - 化合物在制备用于治疗免疫性疾病的药物中的用途 - Google Patents

化合物在制备用于治疗免疫性疾病的药物中的用途 Download PDF

Info

Publication number
CN100558368C
CN100558368C CNB028160916A CN02816091A CN100558368C CN 100558368 C CN100558368 C CN 100558368C CN B028160916 A CNB028160916 A CN B028160916A CN 02816091 A CN02816091 A CN 02816091A CN 100558368 C CN100558368 C CN 100558368C
Authority
CN
China
Prior art keywords
compound
medicament
modified pectin
galectin
pectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028160916A
Other languages
English (en)
Chinese (zh)
Other versions
CN1543352A (zh
Inventor
张岩
V·萨塞克
Original Assignee
Prospect Therapy
GlycoGenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prospect Therapy, GlycoGenesys Inc filed Critical Prospect Therapy
Publication of CN1543352A publication Critical patent/CN1543352A/zh
Application granted granted Critical
Publication of CN100558368C publication Critical patent/CN100558368C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNB028160916A 2001-06-22 2002-06-21 化合物在制备用于治疗免疫性疾病的药物中的用途 Expired - Fee Related CN100558368C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30036001P 2001-06-22 2001-06-22
US60/300,360 2001-06-22
US10/176,022 US20030004132A1 (en) 2001-06-22 2002-06-20 Method and material for treating immune diseases
US10/176,022 2002-06-20

Publications (2)

Publication Number Publication Date
CN1543352A CN1543352A (zh) 2004-11-03
CN100558368C true CN100558368C (zh) 2009-11-11

Family

ID=26871794

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028160916A Expired - Fee Related CN100558368C (zh) 2001-06-22 2002-06-21 化合物在制备用于治疗免疫性疾病的药物中的用途

Country Status (8)

Country Link
US (1) US20030004132A1 (OSRAM)
EP (1) EP1408989A2 (OSRAM)
JP (1) JP2004536825A (OSRAM)
CN (1) CN100558368C (OSRAM)
BR (1) BR0210547A (OSRAM)
CA (1) CA2451885A1 (OSRAM)
IL (1) IL159462A0 (OSRAM)
WO (1) WO2003000195A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522163A (ja) 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US20050158321A1 (en) * 2003-12-17 2005-07-21 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
CN103718046B (zh) * 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
WO2014043708A1 (en) 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US9907814B2 (en) 2012-12-20 2018-03-06 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA3088736A1 (en) * 2018-01-21 2019-07-25 Rensselaer Polytechnic Institute Method of treating galectin-3 dependent disorders
EP3813883A1 (en) 2018-06-29 2021-05-05 Glykos Biomedical Oy Conjugates
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
CA2065265A1 (en) * 1990-06-27 1991-12-28 Tadao Shoji Alkylated oligosaccharides and acetyl derivatives of the same
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies

Also Published As

Publication number Publication date
WO2003000195A3 (en) 2003-03-20
CA2451885A1 (en) 2003-01-03
JP2004536825A (ja) 2004-12-09
IL159462A0 (en) 2004-06-01
EP1408989A2 (en) 2004-04-21
US20030004132A1 (en) 2003-01-02
WO2003000195A2 (en) 2003-01-03
CN1543352A (zh) 2004-11-03
BR0210547A (pt) 2004-05-25

Similar Documents

Publication Publication Date Title
CN100558367C (zh) 化合物在制备用于提高癌症治疗疗效的药物中的用途
CN1543352A (zh) 用于治疗免疫性疾病的方法和材料
Legrand et al. Interactions of lactoferrin with cells involved in immune function
Yan et al. Disruption of the intestinal mucosal barrier in Candida albicans infections
US11666597B2 (en) Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients
AU2002320140A1 (en) Method for enhancing the effectiveness of cancer therapies
SK459890A3 (en) USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT
Rogobete et al. New aspects of controlled release systems for local anaesthetics: a review
CN1794999B (zh) 神经损伤治疗剂
Ruggiero et al. Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)?
Zhang et al. A supramolecular assembly of EGCG for long-term treatment of allergic rhinitis
Balavigneswaran et al. Polysaccharide-Based Self-Healing Hydrogel for pH-Induced Smart Release of Lauric Acid to Accelerate Wound Healing
JP2004536825A5 (OSRAM)
Sahoo et al. Chitosan: The most valuable derivative of chitin
Singh et al. Chitosan hydrogel: Its applications in medicine and dentistry
AU2002320141A1 (en) Method and material for treating immune diseases
Rubanová et al. Intravenous Administration of Hyaluronan in Veterinary Musculoskeletal Disorders: Therapeutic Applications and Mechanisms
EP1996014A1 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
Shaunak Dendrimer drugs prevent scar tissue formation
Wang et al. ROS-responsive phenylboronic acid-modified hyaluronic acid-loaded TA-siRNA nanogels accelerate diabetic wound healing
Mestechkina et al. Effect of polysaccharides on biological activity of human lactoferrin
Malinowska et al. The role of hyaluronic acid in selected diseases
Dhal et al. (Bio) polymeric hydrogels as therapeutic agents
Kalstad et al. Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate
Wadstrom et al. GLYCOSAMINOGLYCAN AND SIALIC ACID BINDING MICROBIAL PROTEIN IN GUT TISSUE ADHESION AND INVASION

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MARBOROUGH RESEARCH CO., LTD.

Free format text: FORMER OWNER: GRIECO GENE SYSTEMS, INC.

Effective date: 20080912

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080912

Address after: Massachusetts

Applicant after: Mar Polo research

Address before: Massachusetts

Applicant before: Glycogenesys Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091111

Termination date: 20100621